The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

@article{Cohen2012TheUO,
  title={The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.},
  author={Alexander A. Cohen and Mark Dobromirski},
  journal={Thrombosis and haemostasis},
  year={2012},
  volume={107 6},
  pages={1035-43}
}
Venous thromboembolism (VTE) is a major healthcare concern and affects more than 1.6 million individuals each year worldwide. Long-term complications include recurrent VTE, chronic thromboembolic pulmonary hypertension and post-thrombotic syndrome. Rivaroxaban is an oral, direct factor Xa inhibitor that has advantages over traditional VTE therapies, including minimal drug and food interactions and no requirement for routine coagulation monitoring. It is currently approved for VTE prevention in… CONTINUE READING
8 Extracted Citations
41 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 41 references

A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism

  • S Schulman, AK Kakkar, SM Schellong
  • (RE-COVER II). Blood (ASH Annual Meeting…
  • 2011
3 Excerpts

About rivaroxaban clinical studies

  • Bayer HealthCare
  • Available at: http://www. xarelto.com/html/press…
  • 2011
1 Excerpt

Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism

  • S Schulman, H Ericsson, SZ Goldhaber
  • J Thromb Haemost 2011; 9 (Suppl
  • 2011
3 Excerpts

Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism

  • S Schulman, D Baanstra, H Eriksson
  • J Thromb Haemost 2011;
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…